Better Therapeutics Valuation
| BTTXDelisted Stock | USD 0.73 0.04 5.19% |
Better Therapeutics is fairly valued. Better Therapeutics shows a prevailing Real Value of $0.72 per share. The current price of the firm is $0.73. Our model approximates the value of Better Therapeutics from analyzing the firm fundamentals such as Current Valuation of 8.83 M, shares owned by insiders of 53.41 %, and Return On Equity of -10.22 as well as examining its technical indicators and probability of bankruptcy. . In general, most investors favor acquiring undervalued instruments and dropping overvalued instruments since, at some point, asset prices and their ongoing real values will blend.
Fairly Valued
Today
Please note that Better Therapeutics' price fluctuation is very steady at this time. Calculation of the real value of Better Therapeutics is based on 3 months time horizon. Increasing Better Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Better otc stock is determined by what a typical buyer is willing to pay for full or partial control of Better Therapeutics. Since Better Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Better OTC Stock. However, Better Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.73 | Real 0.72 | Hype 0.73 | Naive 0.62 |
The intrinsic value of Better Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Better Therapeutics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Better Therapeutics helps investors to forecast how Better otc stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Better Therapeutics more accurately as focusing exclusively on Better Therapeutics' fundamentals will not take into account other important factors: Better Therapeutics Total Value Analysis
Better Therapeutics is currently anticipated to have valuation of 8.83 M with market capitalization of 1.12 M, debt of 14.88 M, and cash on hands of 29.68 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Better Therapeutics fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
8.83 M | 1.12 M | 14.88 M | 29.68 M |
Better Therapeutics Asset Utilization
One of the ways to look at asset utilization of Better is to check how much profit was generated for every dollar of assets it reports. Better Therapeutics shows a negative utilization of assets of -0.95 percent, losing $0.009505 for each dollar of assets held by the firm. Inadequate asset utilization signifies that the company is being less effective with each dollar of assets it shows. Put another way, asset utilization of Better Therapeutics shows how discouraging it operates for each dollar spent on its assets.Better Therapeutics Ownership Allocation
Better Therapeutics holds a total of 54.52 Million outstanding shares. Better Therapeutics retains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.Better Therapeutics Profitability Analysis
Net Loss for the year was (31.57 M) with loss before overhead, payroll, taxes, and interest of (674 K).About Better Therapeutics Valuation
Our relative valuation model uses a comparative analysis of Better Therapeutics. We calculate exposure to Better Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Better Therapeutics's related companies.Better Therapeutics, Inc. engages in developing software-based prescription digital therapeutics platform candidates for treating diabetes, heart disease, and other cardiometabolic conditions in the United States. Better Therapeutics, Inc. was founded in 2015 and is headquartered in San Francisco, California. Better Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 44 people.
8 Steps to conduct Better Therapeutics' Valuation Analysis
OTC Stock's valuation is the process of determining the worth of any otc stock in monetary terms. It estimates Better Therapeutics' potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of otc stock valuation is a single number representing a OTC Stock's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Better Therapeutics' valuation analysis, follow these 8 steps:- Gather financial information: Obtain Better Therapeutics' financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Better Therapeutics' revenue streams: Identify Better Therapeutics' primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Better Therapeutics' industry and market trends, including the size of the market, growth rate, and competition.
- Establish Better Therapeutics' growth potential: Evaluate Better Therapeutics' management, business model, and growth potential.
- Determine Better Therapeutics' financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the OTC Stock's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Better Therapeutics' estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Better Therapeutics Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 23.6 M |
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Portfolio File Import module to quickly import all of your third-party portfolios from your local drive in csv format.
Other Consideration for investing in Better OTC Stock
If you are still planning to invest in Better Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Better Therapeutics' history and understand the potential risks before investing.
| Transaction History View history of all your transactions and understand their impact on performance | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities |